Recce Pharmaceuticals (ASX:RCE) has announced promising new preclinical results demonstrating that its lead anti-infective, RECCE 327, delivered via inhalation, can significantly reduce bacterial burden in a validated mouse model of hospital- and ventilator-acquired pneumonia. …
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - -
Island secures USAMRIID partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News -
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News